Skin barrier as a target for the prediction, prevention, and treatment of atopic dermatitis and food allergy in infancy

Atopic DermatitisAllergic Diseases

Impact of Food Allergy on the Atopic March Progression from Atopic Dermatitis in Early Childhood to Other Atopic Disorders at School Age

J Allergy Clin Immunol Pract

Zeiger RS, Schatz M, Zhou B, Stern JA, Li Q, Basrai S, Stanford RH, Shams M, Avella H, Subramaniam A, Chen W

doi: 10.1016/j.jaip.2025.05.001

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Allergic DiseasesFurther Publications Immunology

Strategic Directions for Advancing Equity in Food Allergy: Takeaways from CFAAR's Summit for Advancing Equity in Food Allergy

J Allergy Clin Immunol Pract

Yang MS, Warren CM, Engel ML, Samady W, Sansweet SR, Kanaley MK, Folger EVW, Shankar S, Gupta RS, Bilaver LA

doi: 10.1016/j.jaip.2025.05.024

Allergic Diseases

Contact Allergy to Preservatives and Emulsifiers in Patients With or Without Atopic Dermatitis

Contact Dermatitis

Houlberg MNA, Nørreslet LB, Wolff ELG, Svendsen SV, Mose KF, Mortz CG

doi: 10.1111/cod.70036

Allergic Diseases

Systematic review and meta-analysis on probiotics as treatment for food allergies among pediatric patients: A 2024 update

Pediatr Allergy Immunol

Tan-Lim CSC, Esteban-Ipac NAR

doi: 10.1111/pai.70028

Atopic Dermatitis

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

Br J Dermatol

Weidinger S, Bewley A, Hong HC, Silvestre JF, Peris K, Wollenberg A, Ivens U, Soehoel A, Steffensen LA, Tindberg AM, Simpson EL

doi: 10.1093/bjd/ljae439

Allergic Diseases

Understanding Experiences, Barriers, and Facilitators of Safe Airline Travel: A Global Survey of Food Allergy Patients and Caregivers

J Allergy Clin Immunol Pract

Warren C, Herbert L, Mandelbaum L, Nowak-Wegrzyn A, Sicherer S, Sampson H, Moassessi C, Gupta R

doi: 10.1016/j.jaip.2024.08.045

Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Br J Dermatol

Gooderham M, Torres T, Imafuku S, Rademaker M, Prajapati VH, Tsianakas A, Murrell DF, Owczarek W, Han Y, Lee WJ, Levy G, Ibrahim N, Moreira A, Shams K

doi: 10.1093/bjd/ljaf236

Atopic Dermatitis

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials

J Am Acad Dermatol

Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, Elmaraghy H, Atwater AR, Pierce E, Xu C, Agell H, Gil EG, Simpson E

doi: 10.1016/j.jaad.2024.12.026

Related content

Impact of Food Allergy on the Atopic March Progression from Atopic Dermatitis in Early Childhood to Other Atopic Disorders at School Age

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Strategic Directions for Advancing Equity in Food Allergy: Takeaways from CFAAR's Summit for Advancing Equity in Food Allergy

Contact Allergy to Preservatives and Emulsifiers in Patients With or Without Atopic Dermatitis

Systematic review and meta-analysis on probiotics as treatment for food allergies among pediatric patients: A 2024 update

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

Understanding Experiences, Barriers, and Facilitators of Safe Airline Travel: A Global Survey of Food Allergy Patients and Caregivers

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials